Gynecologic cancers and in particular ovarian cancer are a major health problem in the United States. The Gynecologic Cancers Program seeks to improve methods of prevention, diagnosis and treatment of gynecologic cancers with a particular focus on ovarian cancer. The Program addresses all aspects of the disease, including underlying biology, molecular pathways, diagnostics and eariy detection, novel therapeutic targets, and clinical trials.
The Specific Aims of the Gynecologic Cancers Program are: 1. To decipher the molecular events that are critical to the development of ovarian cancer, including testing whether a subset of ovarian cancers arise from the fallopian tube. 2. To discover and evaluate novel biomarkers (early detection, prognostic and predictive) in ovarian cancer and to understand their role in the biology of the disease. 3. To utilize molecular technologies to improve the care of women with ovarian cancer, by improving stratification of patients and identifying novel therapeutic targets to Individualize care. 4. To facilitate evaluation of novel therapeutic strategies in the treatment of gynecologic cancers through Phase l/ll clinical trials. The Gynecologic Cancers Program is a multidisciplinary and inter-institutional Program that includes clinical, translational and laboratory-based research efforts. The Program has 52 members representing five DF/HCC institutions. Members span the specialties of medicine, OB/GYN, pathology, surgery, epidemiology, dermatology and radiation oncology. In addition, Program members include basic scientists, molecular pathologists and population scientists. They represent seven departments within Harvard Medical School. The Program has been funded for 11 years and received an excellent score at the last renewal. In 2009, total funding within the Program was $9.4 million, of which $4.3 million is NCI funding and $520,000 is from other peer-reviewed sponsors. Members have published 620 papers in peer-reviewed joumals. Of these, 24% represent Intra-programmatic collaborations, 40% represent inter-programmatic collaborations, and over 21% represent inter-institutional collaborations.
Gynecologic cancers remain a major health problem in this country. In 2010, over 80,000 women will be diagnosed with a gynecologic cancer resulting in approximately 28,000 deaths. A disproportionate number of these deaths (14.000) result from ovarian cancer. This Program seeks to develop better strategies to detect diagnosis and treat women with these cancers. As a result, these efforts should improve both the survival and quality of life of women with gynecologic cancers.
|Chen, Yi-Bin; Batchelor, Tracy; Li, Shuli et al. (2015) Phase 2 trial of high-dose rituximab with high-dose cytarabine mobilization therapy and high-dose thiotepa, busulfan, and cyclophosphamide autologous stem cell transplantation in patients with central nervous system involvement by non-Hodgkin lymphoma. Cancer 121:226-33|
|Waldron, Levi; Haibe-Kains, Benjamin; Culhane, Aedín C et al. (2014) Comparative meta-analysis of prognostic gene signatures for late-stage ovarian cancer. J Natl Cancer Inst 106:|
|Yilmazel, Bahar; Hu, Yanhui; Sigoillot, Frederic et al. (2014) Online GESS: prediction of miRNA-like off-target effects in large-scale RNAi screen data by seed region analysis. BMC Bioinformatics 15:192|
|Mazzola, Emanuele; Chipman, Jonathan; Cheng, Su-Chun et al. (2014) Recent BRCAPRO upgrades significantly improve calibration. Cancer Epidemiol Biomarkers Prev 23:1689-95|
|Zhao, Sihai Dave; Parmigiani, Giovanni; Huttenhower, Curtis et al. (2014) Más-o-menos: a simple sign averaging method for discrimination in genomic data analysis. Bioinformatics 30:3062-9|
|Parkhitko, Andrey A; Priolo, Carmen; Coloff, Jonathan L et al. (2014) Autophagy-dependent metabolic reprogramming sensitizes TSC2-deficient cells to the antimetabolite 6-aminonicotinamide. Mol Cancer Res 12:48-57|
|Cheng, Long; Desai, Jigar; Miranda, Carlos J et al. (2014) Human CFEOM1 mutations attenuate KIF21A autoinhibition and cause oculomotor axon stalling. Neuron 82:334-49|
|Akbay, Esra A; Moslehi, Javid; Christensen, Camilla L et al. (2014) D-2-hydroxyglutarate produced by mutant IDH2 causes cardiomyopathy and neurodegeneration in mice. Genes Dev 28:479-90|
|Brunner, Andrew M; Blonquist, Traci M; Sadrzadeh, Hossein et al. (2014) Population-based disparities in survival among patients with core-binding factor acute myeloid leukemia: a SEER database analysis. Leuk Res 38:773-80|
|Karamichos, D; Hutcheon, A E K; Rich, C B et al. (2014) In vitro model suggests oxidative stress involved in keratoconus disease. Sci Rep 4:4608|
Showing the most recent 10 out of 177 publications